Actinium Pharmaceuticals, Inc.
AMEX:ATNMBiotechnology
+$0.22 today
- Market cap
- $51.56M
- Beta
- 0.02
- P/E (TTM)
- 4.4
- EPS (TTM)
- $0.36
Volume 0.18M
Average 0.15M
ATNM Other Non-Cash Items
Other non-cash adjustments that reconcile net income to operating cash flow.
Actinium Pharmaceuticals, Inc.AMEX: ATNM
Other Non-Cash Items · Q2 FY2026 · quarter ended Jun 2026
Other non-cash items outflow grows to $1.21M
Q2 FY2026 other non-cash items was $1.21M, compared with $0 a year earlier. Trailing-twelve-month other non-cash items was $1.23M.
Context
- Other non-cash items amounted to 0.0% of revenue in FY2025.
- Other non-cash items increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly other non-cash items holds near $1.21M or moves back toward the trailing-twelve-month quarterly average of $306.25K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Other Non-Cash Items history
USD · from the cash flow
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Other Non-Cash Items | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | +100.0% |
| FY2022 | 2022-12-31 | (402K) | -126.0% |
| FY2021 | 2021-12-31 | 1.55M | — |
Other Non-Cash Items vs competitors
How ATNM compares with its peers on the latest reported figures
- ATNM's LTM Jun 2026 other non-cash items of $1.23M is the 3rd largest of the 5 companies compared; the peer median is $2.87M.
- Other non-cash items amounts to 3.5% of revenue for ATNM, versus a peer median of 10.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $20.21B | +1471660.5% | +482.8% | — | |
| LTM Mar 2026 | $5.74M | -116.5% | — | 10.7% | |
| LTM Jun 2026 | $1.23M | — | — | 3.5% | |
| LTM Mar 2026 | $148K | -96.6% | — | — | |
OKUROnKure Therapeutics, Inc. | LTM Mar 2026 | $6K | -99.7% | — | — |
| Peer median (excluding ATNM) | $2.87M | -98.1% | +482.8% | 10.7% | |
Competitors are the stored peer set for ATNM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (24.77M) | (33.02M) | (48.82M) | (38.24M) | (33.89M) |
| Depreciation & Amortization | 524K | 699K | 790K | 811K | 821K |
| Deferred Income Tax | (1.55M) | 402K | 0 | 0 | 0 |
| Stock-Based Compensation | 1.69M | 2.8M | 3.84M | 5.29M | 9.19M |
| Change in Working Capital | 1.69M | 38.17M | (3.15M) | (932K) | (704K) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.2M | 4.6M | (2.18M) | (387K) | (346K) |
| Other Working Capital | 495K | 33.57M | (972K) | (545K) | (358K) |
| Other Non-Cash Items | 1.55M | (402K) | 0 | 0 | 0 |
| Operating Cash Flow | (20.87M) | 8.64M | (47.34M) | (33.07M) | (24.58M) |
| Capital Expenditures | (133K) | (366K) | (153K) | (11K) | (104K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (133K) | (366K) | (153K) | (11K) | (104K) |
| Debt Repayment | (85K) | (49K) | (4K) | (9K) | (10K) |
| Common Stock Issued | 35.3M | 23.16M | 14.87M | 29.26M | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | (207K) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 6K | 0 | 0 | 75K | 0 |
| Financing Cash Flow | 35.22M | 23.11M | 14.87M | 29.32M | (217K) |
| Effect of Forex Changes | 0 | 0 | (11K) | 0 | 6K |
| Net Change in Cash | 14.22M | 31.39M | (32.63M) | (3.76M) | (24.9M) |
| Free Cash Flow | (21M) | 8.28M | (47.49M) | (33.08M) | (24.68M) |
Actinium Pharmaceuticals, Inc.
AMEX:ATNM
Intrinsic Alpha fair value
Locked
Current Price
$1.64
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.